NVX-207

• Description :

  NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC50=3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP[1].

• CAS Number :

  [745020-66-0]

• UNSPSC :

  12352211

• Target :

  Apoptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/NVX-207.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](OC(C)=O)C5(C)C)C)C)([H])[C@@]4(C)CC1)OCC(CO)(N)CO

• Molecular Formula :

  C36H59NO6

• Molecular Weight :

  601.86

• References & Citations :

  [1]Willmann M, et al. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest. 2009;39 (5) :384-394.|[2]Bache M, et al. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci. 2014 Oct 30;15 (11) :19777-90.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported